29 Paliatywna jednofrakcyjna brachyterapia HDR u chorych na zaawansowanego miejscowo niedrobnokomórkowego raka płuca

Kasprowicz, Anetta; Kulik, Anna; Łyczek, Jarosław; Dolińska, H.; Olszewska, A.

doi:10.1016/s1507-1367(00)70347-6

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lack of clear consensus regarding the value of doses used in BT is the reason why different fraction doses are used in clinical treatment [ 1 ]. Due to bad performance status (Zubrod-ECOG-WHO score ≥ 2), single high doses ranging from 10 Gy to 15 Gy are applied [ 14 , 15 ]. It seems that results in this procedure are similar to whenever doses were given weekly in two or three fractions.…”

Section: Purposementioning

confidence: 99%

Brachytherapy in the treatment of lung cancer – a valuable solution

Skowronek¹

2015

jcb

View full text Add to dashboard Cite

The majority of patients with lung cancer are diagnosed with clinically advanced disease. Many of these patients have a short life expectancy and are treated with palliative aim. Because of uncontrolled local or recurrent disease, patients may have significant symptoms such as: cough, dyspnea, hemoptysis, obstructive pneumonia, or atelectasis. Brachytherapy is one of the most efficient methods in overcoming difficulties in breathing that is caused by endobronchial obstruction in palliative treatment of bronchus cancer. Efforts to relieve this obstructive process are worthwhile, because patients may experience improved quality of their life (QoL). Brachytherapy plays a limited but specific role in definitive treatment with curative intent in selected cases of early endobronchial disease as well as in the postoperative treatment of small residual peribronchial disease. Depending on the location of the lesion, in some cases brachytherapy is a treatment of choice. This option is fast, inexpensive, and easy to perform on an outpatient basis.Clinical indications, different techniques, results, and complications are presented in this work.

show abstract

Section: Purposementioning

confidence: 99%

Brachytherapy in the treatment of lung cancer – a valuable solution

Skowronek¹

2015

jcb

View full text Add to dashboard Cite

show abstract

“…Due to bad performance status (Karnofsky score < 50) single high doses ranging from 10 Gy to 15 Gy are used [3,11,13]. It seems that the results achieved are similar to those when doses are given weekly in two or three fractions.…”

Section: Introductionmentioning

confidence: 99%

High dose rate endobronchial brachytherapy in the management of advanced lung cancer – comparison of different doses – preliminary assessment

Skowronek

Adamska

Zwierzchowski

et al. 2002

Reports of Practical Oncology & Radiotherapy

View full text Add to dashboard Cite

Purpose: Brachytherapy is one of the most efficient methods of overcoming endobronchial obstruction in palliative treatment of lung cancer. In single cases, brachytherapy is performed as radical treatment, however in most of cases, due to advanced clinical stage it has a palliative aim. In the absence of clear consensus regarding the value of doses used in brachytherapy different fraction doses are used in clinical treatment. The aim of this work is to compare results of palliative high dose rate brachytherapy using various treatment protocols with the view to analysing differences in survival and diminishing breathing difficulties. Material and methods: Between May 1999 and February 2000 at the Greatpoland Cancer Center, 69 patients with advanced lung cancer were treated by high dose rate brachytherapy. They were disqualified from radical treatment due to advanced clinical stage. The age of the patients ranged from 39 to 76 years (average 53,2 years). Fifty-one patients received a total dose of 22,5 Gy in 3 fractions once a week, 18 patients received one single fraction of 10 Gy. All the patients were divided into two groups according to their clinical stage and the Karnofsky score-those with the Karnofsky score lower than 50 were qualified for a single fraction treatment. They were under clinical and endobronchial observation as regards survival rates, local remission and subsiding dyspnoea, breathing, cough and haemoptysis in the first, third, sixth and twelveth month of observation. Results: Four weeks after the end of treatment subjective improvement (subsidence of all symptoms) was ascertained in 61/69 (88,4%) patients. In 12 cases (17,4%) complete remission (CR), in 49 cases (71,0%)-partial remission (PR) of the tumor were found. During one year of observation 45 (65,2%) patients died, in 10 cases (14,5%) improvement of in dyspnoea was observed and in 14 cases (20,3%) recurrence and progression of the disease were noted. There was no statistical difference in the survival rates between the two groups of patients treated with different fractions protocols. Conclusions: 1. Brachytherapy in advanced lung cancer is an efficient method that led in most of patients to subcidence of symptoms and to improvement of the quality their lives. 2. The two treatment protocols showed similar efficiency in overcoming difficulties in breathing. 3. Survival rates were similar in both group of patients treated with different treatment protocols.

show abstract

29 Paliatywna jednofrakcyjna brachyterapia HDR u chorych na zaawansowanego miejscowo niedrobnokomórkowego raka płuca

Cited by 2 publications

References 0 publications

Brachytherapy in the treatment of lung cancer – a valuable solution

Brachytherapy in the treatment of lung cancer – a valuable solution

High dose rate endobronchial brachytherapy in the management of advanced lung cancer – comparison of different doses – preliminary assessment

Contact Info

Product

Resources

About